Marketing analysis: merck & co., inc. & pfizer inc.

Marketing Analysis: Merck & Co., Inc. & Pfizer Inc. Marketing Analysis: Merck & Co., Inc. & Pfizer Inc. Originally, marketing drugs involved heavy coordination with the sales or “rep” force. Companies would often call up seminars with doctors, hospital workers, or any other workers in the healthcare industry to help promote the product according to the specificity of the drug and specialty of the field. 1. Rep Schedules times with Doctors before hand 2. Sales rep comes in for a few minutes 3. Sales rep advertises and explains the product or drug 4. Free samples and promotional materials are handed out There was some abuse to this sales rep force as many would give biased information or bother the convenience of the doctor with his patients. Eventually, M.D.s began to restrict and even prohibit the welcoming of pharmaceutical sales reps within the company. By 2005, many of the larger firms decided to hire “large payors and PBMs as well as individual doctors” to market their drug (Collis and Smith 707-509). Nonetheless, the value of the free samples increased drastically between 1996 and2005 Promotional Spending Type
(USD in Millions)

Value of Free Samples
Pharmaceutical Companies also marketed towards the “widely respected physicians who were instrumental in the adoption of a new drug by setting prescribing standards” (Collis and Smith 707-509). Companies would often set up joint-ventures with vaccines and drugs in adjunct with the academic community and the graduate school realms to foster the “opinion leaders”. In the recent years, Direct to Consumer Advertising became a phenomenal marketing source for the pharmaceutical companies. Studies show that “60% of the patients who discussed a specific drug with their doctors received a prescription for it.” With a well-educated America, it became more effective to sell the specific drugs directly to the market with no intermediary person such as Physician or Healthcare worker. In general, the Major Drugs has switched from to a more Selective Market Exposure to a Direct Distribution. Merck & Co., Inc. Marketing Strategies Orientation According to one marketing manager, Merck Research Labs “gave us the drug, it was best in class, and we sold it. Marketing was „allowed‟ in much later in the process. It was a good strategy, Orientation. According to the quote, Merck was much more interested on the research and the ability of the product to sell itself, marketing would only be an accelerating factor to help sell the product. However, Merck has been switching to the Market Orientation strategy. Now Merck is more concerned, with the rise of competing Generics, to focus on more of advertising and commercialization. Currently Merck’s Marketing Campaign has changed in the following ways:  “Key Franchise” Management – Offering data and percentages to substantiate the drug  New Sales forces were organized to bolster top selling drugs  Reps were to promote simultaneous drugs to offer opinions and choices  Reps visiting the same doctors were reduced  Meetings were setup with doctors to discuss the drug’s efficacy Price Pfizer: Tactic: increasing the price of old drugs, developing new drugs Example: the price of Lipitor rose by 16% Merck: Tactic: cutting the price of drugs Reason: improvements in manufacturing efficiency; challenge of generic competition Example: lower the price Sustiva by 14%; decided to sell its cholesterol-fighting drug to some major managed-care companies at a lower price Pfizer’s pricing strategy is to raise prices on drugs due to lose of patent protection. By increasing the price of old drugs, Pfizer encourages customers to switch to -- and continue to buy -- similar, newer products developed by Pfizer that enjoy market exclusivity well in the future. For example, Pfizer raised the price of the world's top-selling drug--cholesterol-fighting Lipitor, which will lose its patent protection in 2011by 16%. However, Merck’s pricing strategy is to cut the price of drugs due to both the improvements in its manufacturing efficiency and the challenge of generic competition. For example, Merck has agreed to lower the price of HIV med which is known as Sustiva in the U.S., by 14% due to the improvement of efficiency. Facing the challenge of generic competition, it also decided to sell its cholesterol-fighting drug to some major managed-care companies at a lower price

Source: http://magus9653.files.wordpress.com/2008/11/market-analysismrkpfe.pdf

aqnmol.kw.ac.kr

Collaborative Conference on Materials Research (CCMR) 2012 Time: June 25 – June 29, 2012 Venue: Seoul Palace Hotel, Seoul, Korea Talk title Material Research Session: Quantum dot (Chair: Zhiming M. Wang) Quantum dot – microlasers with external feedback – a chaotic system close to the quantum limit InAs/InP (100) quantum dots in InP photonic GaAs single quantum emitters

Microsoft word - #2 the glorious transformation.doc

THE GLORIOUS TRANSFORMATION “But we all, with unveiled face, behold as in a mirror the glory of the Lord, are being transformed into the same image from glory to glory by the Spirit of the Lord.” OBJECTIVE: The transforming power of Jesus Christ changes and equips ordinary people who live ordinary lives to influence extraordinary for the glory of God. OPENING: Ephesians 1:1-14

Copyright © 2009-2018 Drugs Today